Minodronic acid
Names | |
---|---|
IUPAC name
(1-Hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid | |
Other names
Minodronate; YM 529 | |
Identifiers | |
180064-38-4 155648-60-5 (hydrate) | |
ChEMBL | ChEMBL319144 |
ChemSpider | 115805 |
| |
Jmol-3D images | Image |
PubChem | 130956 |
| |
Properties | |
Molecular formula |
C9H12N2O7P2 |
Molar mass | 322.15 g·mol−1 |
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | |
verify (what is: / ?) | |
Infobox references | |
Minodronic acid is a third-generation bisphosphonate drug. It is approved for use in Japan for the treatment of osteoporosis.[1] Its mechanism of action involves inhibition of farnesyl pyrophosphate synthase activity.[2]
References
- ↑ Shridhar Hegde and Michelle Schmidt (2009). "To Market, To Market - 2009. 16. Minodronic acid". Annual Reports in Medicinal Chemistry 45: 509–510. doi:10.1016/s0065-7743(10)45028-9.
- ↑ Sorbera, L.A.; Castañer, J.; Leeson, P.A. (2002). "Minodronic Acid". Drugs of the Future 27 (10): 935–941. doi:10.1358/dof.2002.027.10.701186.